HPV in Nepal — Human Papillomavirus Testing, Vaccination & Care The Commonest STI — High-Risk vs Low-Risk, Screening & Prevention

What HPV Is

Human papillomavirus is commonest sexually transmitted infection — most sexually active adults acquire it at some point, and most infections clear naturally within about two years without producing anything. The clinical division is between low-risk types (mostly 6 and 11, which cause genital warts) and high-risk types (especially 16 and 18, which drive cervical and several other cancers).

The cancer pathway is one that matters: persistent high-risk HPV over years produces cervical cell changes that precede cancer — detected by cervical screening (HPV DNA and/or cytology) at stage where treatment prevents it. Cervical cancer is one of most preventable cancers — most cases are prevented by screening and vaccination.

There is no treatment for virus itself — management is surveillance of persistent infections and treatment of consequences (warts, precancerous lesions). This shapes everything about how HPV is handled: screening, vaccination and management, not a drug that removes virus.

High-Risk vs Low-Risk Types

Low-risk HPV — mostly types 6 and 11 — causes genital warts: visible, treatable, and not cancer-causing. The warts are cosmetic and transmission concern; their oncological significance is nil.

High-risk HPV — especially 16 and 18, plus a dozen others — causes no visible disease but drives cell changes that precede cervical cancer and several other cancers (anal, oropharyngeal, penile, vulvar, vaginal). The high-risk type is oncological concern — detected by screening, managed by surveillance and lesion treatment.

Cervical Screening

Cervical screening is cancer-prevention core: HPV DNA testing detects high-risk types; cytology ( smear) identifies abnormal cells; co-testing combines them. Screening catches persistent infections at stage where intervention prevents cancer — before symptoms, before disease.

Intervals are typically ~3–5 years for negative co-tests — shorter where results warrant closer surveillance. A positive high-risk result is surveillance, not cancer: virus is present, closer monitoring is indicated, and most positives never progress.

Genital Warts

Genital warts — visible HPV manifestation — are caused by low-risk types 6/11. Diagnosed visually by an experienced clinician; treated by removal or destruction (cryotherapy, topical agents, surgical removal) matched to lesions.

Treatment clears lesions but not virus — ~30%+ recur within months because virus persists. Recurrence is managed, not a treatment failure; viral activity typically declines over time.

Vaccination & Prevention

HPV vaccination prevents large majority of HPV-driven disease — cervical cancer, most anal and oropharyngeal cancers, and genital warts. Most effective before exposure — ideally adolescence — but beneficial for many adults depending on prior exposure; eligibility is assessed honestly by age and history.

Vaccination does not end screening — it reduces but does not eliminate risk, and vaccinated women still screen at standard intervals. Barrier protection reduces but does not eliminate transmission — HPV spreads skin-to-skin beyond what barriers cover.

HPV Services & Costs

Transparent pricing; confirm when booking.

Related Services & Guides